Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic
Cardiomyopathy

J 2015

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

RŮŽEK, Lukáš; Tomas KONECNY; Filip SOUČEK; Dana KONECNY; Lukáš MACH et al.

Základní údaje

Originální název

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Autoři

RŮŽEK, Lukáš; Tomas KONECNY; Filip SOUČEK; Dana KONECNY; Lukáš MACH; Steve R. OMMEN; Stephen L. KOPECKY a Rick A. NISHIMURA

Vydání

American Journal of Cardiology, Bridgewater, Excerpta Medica Inc-Elsevier Science Inc, 2015, 0002-9149

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.154

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083489

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Hypertrophic cardiomyopathy; male sexual dysfunction; phosphodiesterase type 5; sildenafil

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 11. 2015 12:51, Soňa Böhmová

Anotace

V originále

The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.

Citovat

RŮŽEK, Lukáš; Tomas KONECNY; Filip SOUČEK; Dana KONECNY; Lukáš MACH; Steve R. OMMEN; Stephen L. KOPECKY a Rick A. NISHIMURA. Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. American Journal of Cardiology. Bridgewater: Excerpta Medica Inc-Elsevier Science Inc, 2015, roč. 116, č. 4, s. 618-621. ISSN 0002-9149. Dostupné z: https://doi.org/10.1016/j.amjcard.2015.05.022.

@article{1307113,
   author = {Růžek, Lukáš and Konecny, Tomas and Souček, Filip and Konecny, Dana and Mach, Lukáš and Ommen, Steve R. and Kopecky, Stephen L. and Nishimura, Rick A.},
   article_location = {Bridgewater},
   article_number = {4},
   doi = {https://doi.org/10.1016/j.amjcard.2015.05.022},
   keywords = {Hypertrophic cardiomyopathy; male sexual dysfunction; phosphodiesterase type 5; sildenafil},
   language = {eng},
   issn = {0002-9149},
   journal = {American Journal of Cardiology},
   title = {Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy},
   url = {http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract},
   volume = {116},
   year = {2015}
}

TY  - JOUR
ID  - 1307113
AU  - Růžek, Lukáš - Konecny, Tomas - Souček, Filip - Konecny, Dana - Mach, Lukáš - Ommen, Steve R. - Kopecky, Stephen L. - Nishimura, Rick A.
PY  - 2015
TI  - Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy
JF  - American Journal of Cardiology
VL  - 116
IS  - 4
SP  - 618-621
EP  - 618-621
PB  - Excerpta Medica Inc-Elsevier Science Inc
SN  - 00029149
KW  - Hypertrophic cardiomyopathy
KW  - male sexual dysfunction
KW  - phosphodiesterase type 5
KW  - sildenafil
UR  - http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract
L2  - http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract
N2  - The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.
ER  -

RŮŽEK, Lukáš; Tomas KONECNY; Filip SOUČEK; Dana KONECNY; Lukáš MACH; Steve R. OMMEN; Stephen L. KOPECKY a Rick A. NISHIMURA. Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. \textit{American Journal of Cardiology}. Bridgewater: Excerpta Medica Inc-Elsevier Science Inc, 2015, roč.~116, č.~4, s.~618-621. ISSN~0002-9149. Dostupné z: https://doi.org/10.1016/j.amjcard.2015.05.022.

Přehled o publikaci